Korean Biopharmaceutical Stocks: Beware of Overstating Moderna Cancer Vaccine Benefits
Jump to 3:16While Moderna's cancer vaccine development is real, analysis suggests that vague expectations of Korean biopharmaceutical stocks benefiting from Moderna are excessive. There is still a technological gap between Korean companies and large US pharmaceutical firms, and short-term surges due to already-exposed news should be viewed with caution.
It's a big misconception to think that Korean biopharmaceutical stocks will surge as if they are direct beneficiaries of Moderna.


